Recent development and advances on the fabrication and biomedical applications of nanoparticles-based drug delivery systems for metformin

2021 ◽  
Author(s):  
Xiaowei Yang ◽  
Qi Lai ◽  
Xinmin Yang ◽  
Banglin Xie ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Drug Delivery ◽  
Biomedical Applications ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Hypoglycemic Agents ◽  
Important Class ◽  
Oral Hypoglycemic Agents

Metformin is an important class of oral hypoglycemic agents for type 2 diabetes via inhibiting gluconeogenesis in liver and increasing the sensitivity of receptor to insulin. It also displayed a...

Rediscovering Tocophersolan: a renaissance for nano-based drug delivery and nanotheranostic applications

2020 ◽  
Vol 21 ◽  
Author(s):  
Dickson Pius Wande ◽  
Qin Cui ◽  
Shijie Chen ◽  
Cheng Xu ◽  
Hui Xiong ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Biomedical Applications ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Drug Dissolution ◽  
Glycol Succinate ◽  
Permeation Enhancer ◽  
P Glycoprotein ◽  
Us Fda ◽  
Anticancer Compound

: As a unique and pleiotropic polymer, d-alpha-tocopheryl polyethylene glycol succinate (Tocophersolan) is a polymeric synthetic version of vitamin E. Tocophersolan has attracted enormous attention as a versatile excipient in different biomedical applications including drug delivery systems and nutraceuticals. The multiple inherent properties of Tocophersolan make it play flexible roles in drug delivery system design, including excipients with outstanding biocompatibility, solubilizer with the ability of promoting drug dissolution, drug permeation enhancer, P-glycoprotein inhibitor and anticancer compound. For these reasons, Tocophersolan has been widely used for improving the bioavailability of numerous pharmaceutical active ingredients. Tocophersolan has been approved by stringent regulatory authorities (such as US FDA, EMA, and PMDA) as a safe pharmaceutical excipient. In this review, we systematically curated current advances in nano-based delivery systems consisting of Tocophersolan with possibilities for futuristic applications in drug delivery, gene therapy, and nanotheranostic.

Lanthanide-doped upconversion nanoparticles complexed with nano-oxide graphene used for upconversion fluorescence imaging and photothermal therapy

2018 ◽  
Vol 6 (4) ◽  
pp. 877-884 ◽  
Author(s):  
Po Li ◽  
Yue Yan ◽  
Binlong Chen ◽  
Pan Zhang ◽  
Siling Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Fluorescence Imaging ◽  
Photothermal Therapy ◽  
Biomedical Applications ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Research Interest ◽  
Upconversion Nanoparticles ◽  
Multifunctional Nanoparticles ◽  
Nano Oxide

In recent years, multifunctional nanoparticles have attracted much research interest in various biomedical applications such as biosensors, diagnosis, and drug delivery systems.

scholarly journals A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes

2018 ◽  
Vol 2018 ◽  
pp. 1-9
Author(s):  
Shuo Lin ◽  
Mu Chen ◽  
Wanling Chen ◽  
Keyi Lin ◽  
Panwei Mu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Insulin Infusion ◽  
Cell Function ◽  
Hypoglycemic Agents ◽  
Newly Diagnosed ◽  
Oral Hypoglycemic Agents

Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensive antihyperglycemic treatment in people with newly diagnosed type 2 diabetes. This study is aimed at comparing the short-term (over a period of 12 days) effects of basal insulin glargine plus OHAs and continuous subcutaneous insulin infusion (CSII) on glycemic control and beta-cell function in this setting. Methods. An open-label parallel-group study. Newly diagnosed hospitalized patients with type 2 diabetes and fasting plasma glucose (FPG) ≥11.1 mmol/L or glycated hemoglobin (HbA1c) ≥9% (75 mmol/mol) were randomized to CSII or insulin glargine in combination with metformin and gliclazide. The primary outcome measure was the mean amplitude of glycemic excursions (MAGE), and secondary endpoints included time to reach glycemic control target (FPG < 7 mmol/L and 2-hour postprandial plasma glucose < 10 mmol/L), markers of β-cell function, and hypoglycemia. Results. Subjects in the CSII (n=35) and basal insulin plus OHA (n=33) groups had a similar significant reduction from baseline to end of treatment in glycated albumin (−6.44 ± 3.23% and− 6.42 ± 3.56%, P=0.970). Groups A and B have comparable time to glycemic control (3.6 ± 1.2 days and 4.0 ± 1.4 days), MAGE (3.40 ± 1.40 mmol/L vs. 3.16 ± 1.38 mmol/L; p=0.484), and 24-hour mean blood glucose (7.49 ± 0.96 mmol/L vs. 7.02 ± 1.03 mmol/L). Changes in the C-peptide reactivity index, the secretory unit of islet in transplantation index, and insulin secretion-sensitivity index-2 indicated a greater β-cell function improvement with basal insulin plus OHAs versus CSII. Conclusions. Short-term insulin glargine plus OHAs may be an alternative to CSII for initial intensive therapy in people with newly diagnosed type 2 diabetes.

scholarly journals Patterns of Adherence to Oral Hypoglycemic Agents and Glucose Control among Primary Care Patients with Type 2 Diabetes

2014 ◽  
Vol 42 (2) ◽  
pp. 63-71 ◽  
Author(s):  
Heather F. de Vries McClintock ◽  
Knashawn H. Morales ◽  
Dylan S. Small ◽  
Hillary R. Bogner
Keyword(s):  
Type 2 Diabetes ◽  
Primary Care ◽  
Glucose Control ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Primary Care Patients

scholarly journals The importance and advantages of the timely prescription of insulin to the patients with type 2 diabetes mellitus

2012 ◽  
Vol 58 (3) ◽  
pp. 56-60
Author(s):  
I R Iarek-Martynova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Therapy ◽  
Clinical Situation ◽  
Hypoglycemic Agents ◽  
Negative Consequences ◽  
Oral Hypoglycemic Agents ◽  
Adequate Treatment

The onset of insulin therapy is an important stage in the treatment of type 2 diabetes mellitus. Its timely beginning ensures better control of glycemia and reduces the negative consequences of chronic glucose cytotoxicity and lipotoxicity. The achievement and maintenance of the stable compensation of the disease are the indispensable conditions for successful prophylaxis and adequate treatment of chronic complications of diabetes mellitus. The ADA guidelines recommend to initiate insulin therapy at the early stages of the disease provided it is dictated by the clinical situation or combine it with the use of oral hypoglycemic agents if the targeted HbA1c levels fail to be reached despite the intake of one or more tableted preparations.

Sign in / Sign up

Export Citation Format

Share Document